Aura Biosciences, Inc.
AURAHealthcare|Biotechnology|US
$6.56
+0.22 (+3.47%)
DCF Value
$0.67
Tangible Book / Share
$3.32
Cash / Share
$3.41
About
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Stock Price
+21.3%(1Y)
1M
+0.8%
3M
-17.9%
6M
-21.9%
YTD
+20.4%
1Y
+18.8%
3Y
-10.9%
5Y
-58.5%
Pipeline Summary
22 total trials2
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
Active: 4Completed: 11Terminated: 1Unknown: 2By Invitation: 1Not Yet Recruiting: 1Recruiting: 2
Active Trials (6)
Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects
NCT07421739Choroidal Melanoma
Active
Enrollment: 15 participants
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma
Phase 3Active
Enrollment: 108 participants
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
NCT03941379Choroidal Melanoma
Active
Enrollment: 63 participants
Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884Eye Cancer
Phase 2Recruiting
Enrollment: 24 participants
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
NCT05483868Non-muscle-invasive Bladder Cancer
Phase 1Active
Enrollment: 55 participants
Key Facts
Market Cap$680.3M
Employees113 (+7% YoY)
CEONatalie C. Holles
IPO DateOct 29, 2021
Beta0.41
52-Week Range$4.73 – $9.54
Avg Volume779,659
ExchangeNASDAQ
Websiteaurabiosciences.com
Ownership
Float72.0%
Shares Outstanding103.7M
Recent Insider Trades
Person JulieAWARD
Sep 1, 2026212,389 shares @ $7.43
Person JulieAWARD
Sep 1, 2026107,611 shares
Kratz EricaAWARD
Sep 1, 2026199,115 shares @ $7.43
Kratz EricaAWARD
Sep 1, 2026100,885 shares
Hopkins Janet JillAWARD
Sep 1, 202658,850 shares
Peers
Recent News
Aura Biosciences to Participate in Upcoming Investor Conference
Nov 3, 2026 · globenewswire.com
Aura Biosciences: A Pivotal Trial Engineered With Room To Spare
Oct 31, 2026 · seekingalpha.com
Aura Biosciences, Inc. (AURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sep 16, 2026 · seekingalpha.com
Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.
Sep 7, 2026 · defenseworld.net
Aura Biosciences to Participate in Upcoming Investor Conference
Sep 2, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 03:57 AM